Therapeutic Benefit
Our best-in-class HDAC6 targeting molecules deliver improved drug-like features, enabling us to advance towards potentially life-changing treatments for debilitating diseases
Next-gen targeting for breakthrough medicines
Breaking Barriers
Conventional drug design approaches have been constrained by their ability to effectively target disease driver proteins, resulting in the failure to translate into meaningful drugs for patients.
Our proprietary technology unlocks a novel binding mechanism to HDAC6, a target with strong validation across renal, cardiometabolic and neurological diseases. By solving the potency, selectivity, and drug-likeness issues that have held back earlier HDAC6 inhibitors, we are building oral medicines suited to unlock the full therapeutic potential of HDAC6 targeting, and ultimately deliver better patient outcomes.
Precision Platform
Driven by a decade of foundational research, HDAX’s medicinal chemistry expertise pushes the boundaries of HDAC6 targeting. The result is a best-in-class potential approach: highly potent, selective small molecules designed to solve the critical drug-design challenges that have held back the class.
Our molecules achieve strong, selective and durable HDAC6 target engagement, built for the oral, long-term dosing needed to treat chronic diseases across diverse indications.
Behind the science: Scientist founders and seasoned drug developers who know the path from bench to clinic, and are walking it again
HDAX Advantage
Target Safety
HDAC6 offers a wide safety window that broadly acting HDAC inhibitors lack. Our selective chemistry is designed to support the needs for chronic diseases.
Multi-Indication Application
HDAC6’s roles in cilia, microtubule function, cytoskeleton dynamics and inflammation make it a sought-after target for disease modification across many indications.
HDAX precision targeting platform has boundless possibilities
